Regulatory Oversight Wegovy underwent extensive clinical trials involving thousands of participants before receiving FDA approval
The practical tradeoffs between the two methods come down to time, customization, and cost
These are similar to the adverse event rates seen with injectable semaglutide

(PDF) Harnett, N.G., Joshi, S., Kumar, P., Russell, C., Dillon, D.G., Baker, J.T., Pizzagalli, D.A., Kaufman, M.L., Nickerson, L.N., Jahanshad, N., Salminen, L.E., Thomopoulos, S.I., Frijling, J.L., Veltman, D.J., Koch, S.B.J., Nawijn, L., van Zuiden, M., Zhu, Y., Li, G., Ipser, J., Zhu, X., Ravid, O., Zilcha-Mano, S., Lazarov, A., Suarez-Jimenez, B., Sun, D., Hussain, A., Huggins, A.A., Jovanovic, T., van Rooij, S.J.H., Fani, N., Hudson, A.R., Sierk, A., Manthey, A., Walter, H., van der Wee, N.J.A., van der Werff, S.J.A., Vermeiren, R.R.J.M., ha, P., Lebois, L.A.M., Rosso, I.M., Olson, E.A., Liberzon, I., Angstadt, M., Disner, S.G., Sponheim, S.R., Koopowitz, S.M., Hofmann, D., Qi, R., Maron-Katz, A., Kunch, A., Xie, H., El-Hage, W., Berg, H., Bruce, S.E., McLaughlin, K.A., Peverill, M., Sambrook, K., Ross, M., Herringa, R.J., Nitschke, J.B., Davidson, R.J., deRoon-Cassini, T.A., Tomas, C.W., Fitzgerald, J.M., Blackford, J.U., Olatunji, B.O., Nelson, S.M., Gordon, E.M., Densmore, M., Thberge, J., Neufeld, R.W.J., Olff, M., Wang, L., Stein, D.J., Neria, Y., Stevens, J.S., Mueller, S.C., Daniels, J.K., Rektor, I., King, A., Davenport, N.D., Straube, T., Lu, G., Etkin, A., Wang, X., Quid, Y., Lissek, S., Cisler, J., Grupe, D.W., Larson, C., Feola, B., May, G., Abdallah, C.G., Lanius, R., Thompson, P.M., Morey, R.A., Ressler K

You should not